Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New delta-receptor antagonists.

C W Thornber1, J S Shaw, L Miller

  • 1Department of Chemistry, ICI Pharmaceuticals Division, Alderley Park, Cheshire, UK.

NIDA Research Monograph
|January 1, 1986
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between employees' alcohol consumption, insomnia and HR management strength.

Occupational medicine (Oxford, England)·2024
Same author

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC.

The European physical journal. C, Particles and fields·2022
Same author

Platelet function in dogs with chronic liver disease.

The Journal of small animal practice·2021
Same author

A mixed-methods evaluation of the impact of a pharmacist-led feedback pilot intervention on insulin prescribing in a hospital setting.

Research in social & administrative pharmacy : RSAP·2021
Same author

The Effect of Baseline Performance and Age on Cognitive Training Improvements in Older Adults: A Qualitative Review.

The journal of prevention of Alzheimer's disease·2020
Same author

Photosynthesis and respiration decline with light intensity in dominant and suppressed Eucalyptus globulus canopies.

Functional plant biology : FPB·2020
Same journal

EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES.

NIDA research monograph·2006
Same journal

Problems of drug dependence 1999: Proceedings of the 61st annual scientific meeting, the College on Problems of Drug Dependence, Inc.

NIDA research monograph·2001
Same journal

Problems of drug dependence 1997: proceedings of the 59th annual scientific meeting.

NIDA research monograph·1998
Same journal

Laboratory Behavioral Studies of Vulnerability to Drug Abuse. Proceedings of a meeting. August 2-3, 1994.

NIDA research monograph·1998
Same journal

Disaggregating the liability for drug abuse.

NIDA research monograph·1998
Same journal

Integrating genetic and behavioral models in the study of substance abuse mechanisms.

NIDA research monograph·1998
See all related articles

A novel delta-selective opiate antagonist was synthesized by replacing glycine residues with 4-aminobenzoic acid in diallyl leucine enkephalin. This new compound exhibits a distinct molecular conformation compared to existing antagonists like ICI 174,864.

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • Opiate antagonists are crucial for managing opioid overdose and addiction.
  • Enkephalins are endogenous opioid peptides that modulate pain and reward pathways.
  • Existing antagonists may have limitations in selectivity or conformational properties.

Purpose of the Study:

  • To synthesize a novel delta-selective opiate antagonist.
  • To investigate the structural and conformational properties of the new antagonist.
  • To compare the new compound with existing delta-selective opiate antagonists.

Main Methods:

  • Chemical synthesis of a novel diallyl leucine enkephalin analog.
  • Replacement of glycine residues with 4-aminobenzoic acid.

Related Experiment Videos

  • Conformational analysis of the synthesized compound.

    • Main Results:

    • Successful synthesis of a new delta-selective opiate antagonist.
    • The novel compound possesses a unique molecular conformation.
    • The conformation differs significantly from that of ICI 174,864.

    Conclusions:

    • The modified enkephalin analog represents a new class of delta-selective opiate antagonists.
    • The distinct conformation may influence receptor binding and pharmacological activity.
    • Further studies are warranted to explore the therapeutic potential of this new antagonist.